Brief: Annovis Secures Dsmb Approval To Advance Pivotal Phase 3 Trial Of Buntanetap In Alzheimer’S Disease
12/02/2026 14:39
Feb 12 (Reuters) - Annovis Bio Inc ANVS.N: ANNOVIS SECURES DSMB APPROVAL TO ADVANCE PIVOTAL PHASE 3 TRIAL OF BUNTANETAP IN ALZHEIMER’S DISEASE ANNOVIS BIO INC - DSMB FINDS NO SAFETY CONCERNS, TRIAL TO CONTINUE AS PLANNED Source text: ID:nGNX4b4FX3 Further company coverage: ANVS.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman